Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Merck will showcase results in innovative solutions in HIV treatment and prevention
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Subscribe To Our Newsletter & Stay Updated
